First-Ever Dual Vaccine for Lassa Virus and Rabies Deemed Safe in Human Trial
discovermagazine - Learn more about Lassa virus, which continues to ravage parts of West Africa, and how combining a vaccine against it with rabies protection could address two major health concerns at once.
AI Summary: A first-in-human phase 1 trial of an adjuvanted, inactivated rabies virus–vectored Lassa vaccine met safety and tolerability endpoints in healthy adults, generating immune responses that support further development. The combined platform aims to protect against both Lassa fever and rabies, advancing toward larger trials and evaluation in regions where both diseases are endemic.
Related Stories
Experimental plague vaccine protects immune‑deficient mice from pneumonic plague / 7 wks
Moderna launches mRNA bird‑flu vaccine trial as preparedness ramps up / 4 months
DR Congo Ebola outbreak tops 3,000; Bundibugyo vaccine trial begins / 6 wks
Pfizer's Lyme vaccine heads to FDA after mixed trial results / 5 months
Triple‑dose early treatment clears HIV in newborn primates study / 29 days
UK begins human testing of first AI-designed 'universal' vaccine / 3 months
Favipiravir shows promise in Lassa fever Phase 2 trial / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Infant Health, Rural Health, Health Disparities, Healthcare Finance and look for the RSS link.
StackHealth Time Machine